Amgen (AMGN)

Quick facts

Marketed products

• Prolia · Oncology · revenue 6100
  Prolia works by blocking a protein that breaks down bone.
• Otezla · Immunology · revenue 2100
  Apremilast inhibits PDE4, increasing intracellular cAMP levels, but the exact therapeutic mechanism is unclear.
• Nplate · Cardiovascular · revenue 1524.0
  Nplate works by binding to the thrombopoietin receptor to stimulate platelet production.
• Neupogen · Oncology · revenue 1434.0
  Filgrastim-aafi binds G-CSF receptors on hematopoietic cells, stimulating neutrophil proliferation, differentiation, and functional activation.
• Kyprolis · Oncology · revenue 1300
  Kyprolis works by blocking the proteasome, a complex that breaks down proteins in cells.
• Neulasta · Hematology · revenue 1200
  Colony-stimulating factor binding hematopoietic cell surface receptors to stimulate proliferation and differentiation.
• Blincyto · Oncology · revenue 1000
  Blincyto works by binding to both T cells and cancer cells, directing the T cells to kill the cancer cells.
• Aimovig · Neuroscience · revenue 500
  Aimovig works by blocking the calcitonin-gene-related peptide receptor, a protein involved in migraine pain.
• Aranesp · Hematology · revenue 400
  Aranesp works by binding to the erythropoietin receptor, mimicking the action of natural erythropoietin to stimulate red blood cell production.
• Epogen · Metabolic · revenue 400
  Epogen works by binding to the erythropoietin receptor, triggering a cascade of signals that stimulate the production of red blood cells.
• Epogen · Hematology · revenue 400
  Epoetin alfa stimulates erythropoiesis by the same mechanism as endogenous erythropoietin.
• Lumakras · Oncology · revenue 300
  Lumakras works by covalently binding to the KRAS G12C mutation, thereby blocking the protein's ability to promote cancer cell growth.
• Actonel®
• PAVBLU · Other
• AMG 073 · Endocrinology / Nephrology
  AMG 073 is a calcimimetic agent that allosterically activates the calcium-sensing receptor on the parathyroid gland, increasing its sensitivity to extracellular calcium and thereby suppressing parathyroid hormone secretion.
• AMG334 · Other
• Ammonul · Other
• Anakinra (r-metHuIL-1ra) · Immunology
  Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation.
• Antizol · Metabolic
• Apremilast 30mg
• Bevacizumab-awwb · Oncology
  Bevacizumab-awwb is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) to inhibit tumor angiogenesis and reduce blood supply to cancer cells.
• bisphosphonate · Other
• Buphenyl · Metabolic
• Sensipar · Oncology
  Sensipar works by activating the calcium-sensing receptor, which helps regulate calcium levels in the blood.
• DMARD Therapy
• Drug: Carfilzomib + Dexamethasone · Oncology
  Carfilzomib inhibits the proteasome to trigger cancer cell death, while dexamethasone is a corticosteroid that enhances anti-myeloma effects and reduces inflammation.
• Drug: Carfilzomib + Lenalidomide + Dexamethasone · Oncology
  This three-drug combination kills multiple myeloma cells by inhibiting the proteasome, enhancing immune response to tumor cells, and suppressing tumor-promoting inflammation.
• BKEMV · Other
• Erenumab 140 mg
• Erenumab 70 mg
• erenumab-aooe · Neurology
  Erenumab is a monoclonal antibody that binds to and blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.
• Etanercept (ENBREL®) · Immunology
  Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving immune-mediated diseases.
• Etanercept via Autoinjector A · Immunology
  Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.
• Etanercept via Autoinjector B · Immunology
  Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.
• Etanerept · Other
• gout flare prophylaxis regimen
• HPN-100
• AVSOLA · Other
• Corlanor · Cardiovascular
• Kineret® (Anakinra) · Immunology
  Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation.

Phase 3 pipeline

• 1=Etanercept · Immunology
  Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.
• ABP 206 · Oncology
  ABP 206 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
• ABP 234 · Bone metabolism / Oncology
  ABP 234 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.
• ABP 501 · Immunology / Rheumatology
  ABP 501 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.
• ABP 654 · Bone metabolism / Oncology
  ABP 654 is a monoclonal antibody that blocks RANKL (receptor activator of nuclear factor kappa-B ligand) to inhibit osteoclast formation and bone resorption.
• ABP 692 · Neurology
  ABP 692 is a monoclonal antibody that targets amyloid-beta protofibrils to reduce amyloid pathology in Alzheimer's disease.
• ABP 710 · Immunology / Rheumatology
  ABP 710 is a biosimilar of adalimumab that blocks tumor necrosis factor-alpha (TNF-α) to reduce inflammation.
• ABP 798 · Oncology
  ABP 798 is a bispecific antibody that simultaneously engages CD3 on T cells and PMEL (gp100) on melanoma cells to redirect immune attack against melanoma tumors.
• ABP 938 · Bone metabolism / Osteoporosis
  ABP 938 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.
• ABP 959 · Bone metabolism / Oncology
  ABP 959 is a RANKL inhibitor that blocks osteoclast activation and bone resorption.
• ABP 980 · Oncology
  ABP 980 is a HER2-targeting antibody-drug conjugate that delivers cytotoxic payload to HER2-expressing cancer cells.
• Aeroquin · Other
• AMG 162 · Bone metabolism / Oncology
  AMG 162 is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption.
• AMG 162 / Denosumab · Bone metabolism / Oncology
  Denosumab is a monoclonal antibody that inhibits RANKL, a key regulator of osteoclast formation and bone resorption.
• AMG 531 · Hematology
  AMG 531 is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on megakaryocytes.
• Aranesp® (darbepoetin alfa) · Hematology/Oncology
  Darbepoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to stimulate red blood cell production.
• Background Statin Therapy · Cardiovascular
  Background statin therapy reduces low-density lipoprotein (LDL) cholesterol by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis.
• Buphenyl (NaPBA) · Metabolic/Genetic Disorders
  Buphenyl (sodium phenylbutyrate) provides an alternative pathway for nitrogen excretion by conjugating with glutamine to form phenylacetylglutamine, which is then renally eliminated.
• Commercial Formulation Etanercept · Immunology
  Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.
• Cysteamine Bitartrate Delayed-release Capsules · Rare Genetic Disorder
  Cysteamine bitartrate reduces cystine accumulation in lysosomes by converting cystine to cysteine and cysteamine, thereby decreasing intracellular cystine levels.
• Darbepoetin alfa and Epoetin alfa · Hematology/Oncology
  Darbepoetin alfa and Epoetin alfa are erythropoiesis-stimulating agents that bind to the erythropoietin receptor on bone marrow progenitor cells to stimulate red blood cell production.
• darbepoetin alfa SF · Oncology
  Darbepoetin alfa SF stimulates erythropoiesis by binding to the erythropoietin receptor.
• Denosumab (AMG 162) · Oncology, Bone Metabolism
  Denosumab is a monoclonal antibody that inhibits RANKL, a key signaling molecule that activates osteoclasts and promotes bone resorption.
• Denosumab (CP2) · Oncology, Bone Metabolism
  Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption.
• Denosumab (CP4) · Oncology, Bone Metabolism
  Denosumab is a monoclonal antibody that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand), blocking osteoclast formation and bone resorption.
• Enbrel liquid · Immunology
  Enbrel is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine driving autoimmune and inflammatory diseases.
• Erenumab Dose 1 · Neurology
  Erenumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.
• Etanercept / Autoinjector A · Immunology
  Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.
• Etanercept Liquid · Immunology
  Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.
• EU-authorized Nivolumab · Oncology
  Nivolumab is a monoclonal antibody that blocks PD-1 on T cells, preventing tumor cells from evading immune attack.
• Evolocumab AI/pen · Cardiovascular
  Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.
• Evolocumab AMD · Cardiovascular
  Evolocumab is a PCSK9 inhibitor monoclonal antibody that binds to and inactivates PCSK9 protein, allowing LDL receptors to remain on cell surfaces and increase clearance of LDL cholesterol from the blood.
• Evolocumab Pre-filled Syringe · Cardiovascular
  Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.
• FDA-licensed Nivolumab · Oncology
  Nivolumab blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.
• HyperCVAD · Oncology
  HyperCVAD is a chemotherapy regimen that combines multiple cytotoxic agents to kill rapidly dividing cancer cells through DNA damage and cell cycle disruption.
• HZT-501 · Oncology
  HZT-501 is a bispecific antibody that simultaneously engages two distinct immune pathways to enhance anti-tumor T-cell responses.
• Ibuprofen/famotidine · Pain management / Gastroenterology
  This combination drug reduces stomach acid (via famotidine, an H2-receptor antagonist) while providing anti-inflammatory and analgesic effects (via ibuprofen, an NSAID), designed to minimize gastrointestinal injury from NSAID use.
• interferon γ-1b · Immunology
  Interferon γ-1b enhances immune responses by activating macrophages and natural killer cells, and it also has antiviral properties.
• Irinotecan Based Chemotherapy · Oncology
  Irinotecan is a topoisomerase I inhibitor that prevents DNA religation during replication, leading to DNA damage and cancer cell death.
• Low-intensity chemotherapy regimen · Oncology
  Low-intensity chemotherapy regimens use reduced doses of cytotoxic agents to kill rapidly dividing cancer cells while minimizing toxicity in vulnerable patient populations.

Phase 2 pipeline

• ABX-EGF · Wound healing
  ABX-EGF is a recombinant human heparin-binding EGF-like growth factor.
• AGM 719
• AMG 162 - Prolia · Bone disorders
  AMG 162, also known as Prolia, is a human monoclonal antibody that targets RANKL, a protein involved in bone resorption.
• AMG 193 · Cardiovascular
  AMG 193 is a monoclonal antibody targeting PCSK9.
• AMG 301 · Oncology
  AMG 301 is a monoclonal antibody targeting the interleukin-1 receptor type 1 (IL1R1).
• AMG 334 Dose 1 · Neurology
  AMG 334 is a fully human monoclonal antibody that targets and inhibits the activity of the calcitonin gene-related peptide (CGRP) receptor.
• AMG 714 · Immunology
  AMG 714 is an interleukin-6 (IL-6) receptor antagonist that blocks IL-6 signaling to reduce inflammation.
• AMG 719 · Oncology
  AMG 719 is a bispecific antibody that simultaneously engages CD3 on T cells and FLT3 on acute myeloid leukemia blasts to redirect immune killing.
• AMG 732
• AMG 853 · Cardiovascular
  AMG 853 is a recombinant, humanized monoclonal antibody that targets and neutralizes tissue factor.
• CC-10004
• CC10004
• CCX-354-C · Immunology
  CCX-354-C is a C-C chemokine receptor 4 (CCR4) antagonist that blocks immune cell recruitment to reduce inflammatory responses.
• CCX282-B
• CCX354-C · Inflammatory diseases
  CCX354-C is a monoclonal antibody that targets the IL-1 receptor antagonist (IL-1RA) to prevent IL-1 mediated inflammation.
• Darbepoetin alfa IV
• Darbepoetin alfa SC
• Erenumab PFS
• FPA144 · Oncology
  FPA144 is a monoclonal antibody that blocks fibroblast growth factor receptor 2b (FGFR2b) to inhibit tumor growth and angiogenesis.
• HZN-1116
• IV Bisphosphonate q 4 weeks
• IV Bisphosphonates
• IV iron dextran
• MP-376
• Pre-emptive Skin Treatment
• Previous denosumab
• Reactive Skin Treatment
• Sensipar after Post Transplant
• Systemic AMG 108
• Tezepelumab Dose 1
• VIB4920

Phase 1 pipeline

• [14C]CCX168
• AB248
• ABP 501-HCF
• ABP 501-LCF
• AMG 133
• AMG 172
• AMG 256
• AMG 282
• AMG 305
• AMG 355
• AMG 386, paclitaxel and carboplatin · Oncology
  Angiopoietin-2 inhibitor
• AMG 403
• AMG 410 · Oncology
  Antibody-drug conjugate targeting fibroblast growth factor receptor 3 (FGFR3)
• AMG 436
• AMG 509
• AMG 513
• AMG 529
• AMG 570
• AMG 581
• AMG 592
• AMG 595
• AMG 598
• AMG 609
• AMG 623
• AMG 691
• AMG 786
• AMG 890
• AMG 986
• AMG 994
• Anti-angiogenesis · Oncology
  Inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF)
• Apremilast Immediate Release
• Apremilast IR
• Apremilast Modified Release 1
• Apremilast Modified Release 11
• Apremilast Modified Release 12
• Apremilast Modified Release 13 · Immunology
  Apremilast is a small molecule inhibitor of phosphodiesterase 4 (PDE4), which leads to increased intracellular levels of cyclic adenosine monophosphate (cAMP).
• Apremilast Modified Release 14

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Amgen portfolio CI brief
• Amgen pipeline updates RSS